However, we can suggest the favorable effects of the KIR-HLA genotype combination to improve the effect of NK-cell-based immunotherapy for survival and HCC recurrence to conduct a nationwide, large-scale study. This evidence concerns the gene KIR3DL1 and hepatocellular carcinoma.